These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 8368734)
1. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734 [TBL] [Abstract][Full Text] [Related]
2. Attempts to optimize active specific immunotherapy for melanoma. Mitchell MS Int Rev Immunol; 1991; 7(4):331-47. PubMed ID: 1779176 [TBL] [Abstract][Full Text] [Related]
3. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Kan-Mitchell J; Huang XQ; Steinman L; Oksenberg JR; Harel W; Parker JW; Goedegebuure PS; Darrow TL; Mitchell MS Cancer Immunol Immunother; 1993 Jul; 37(1):15-25. PubMed ID: 8513449 [TBL] [Abstract][Full Text] [Related]
4. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Kan-Mitchell J; Liggett PE; Harel W; Steinman L; Nitta T; Oksenberg JR; Posner MR; Mitchell MS Cancer Immunol Immunother; 1991; 33(5):333-40. PubMed ID: 1831067 [TBL] [Abstract][Full Text] [Related]
5. Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma. LeMay LG; Kan-Mitchell J; Goedegebuure P; Harel W; Mitchell MS Cancer Immunol Immunother; 1993 Aug; 37(3):187-94. PubMed ID: 8101473 [TBL] [Abstract][Full Text] [Related]
6. Active-specific immunotherapy for melanoma. Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701 [TBL] [Abstract][Full Text] [Related]
7. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926 [TBL] [Abstract][Full Text] [Related]
9. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040 [TBL] [Abstract][Full Text] [Related]
10. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Voelkl S; Moore TV; Rehli M; Nishimura MI; Mackensen A; Fischer K Cancer Immunol Immunother; 2009 May; 58(5):709-18. PubMed ID: 18836718 [TBL] [Abstract][Full Text] [Related]
11. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317 [TBL] [Abstract][Full Text] [Related]
12. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses. Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823 [TBL] [Abstract][Full Text] [Related]
13. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity. de Vries JE; Spits H J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458 [TBL] [Abstract][Full Text] [Related]
14. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580 [TBL] [Abstract][Full Text] [Related]
15. Lymphocyte-melanoma interaction: role of surface molecules. Becker JC; Bröcker EB Recent Results Cancer Res; 1995; 139():205-14. PubMed ID: 7597291 [TBL] [Abstract][Full Text] [Related]
16. A CD4+, HLA-DR7-restricted T-helper lymphocyte clone recognizes an antigen shared by human malignant melanoma and glioma. Somasundaram R; Swoboda R; Caputo L; Lee A; Jackson N; Marincola FM; Guerry D; Herlyn D Int J Cancer; 2003 Apr; 104(3):362-8. PubMed ID: 12569560 [TBL] [Abstract][Full Text] [Related]
17. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931 [TBL] [Abstract][Full Text] [Related]
18. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Gervois N; Heuze F; Diez E; Jotereau F Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794 [TBL] [Abstract][Full Text] [Related]
19. Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte-melanoma interactions. Radrizzani M; Benedetti B; Castelli C; Longo A; Ferrara GB; Herlyn M; Parmiani G; Fossati G Int J Cancer; 1991 Dec; 49(6):823-30. PubMed ID: 1835714 [TBL] [Abstract][Full Text] [Related]
20. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]